Insider Sale: Decheng Capital Reports BYSI Dispositions in Sept 2025
Rhea-AI Filing Summary
Decheng Capital entities reported insider dispositions of BeyondSpring Inc. (BYSI) ordinary shares across three days in September 2025. Decheng Capital China Life Sciences USD Fund III sold 2,304 shares on 09/17/2025 at a weighted average price of $1.83, 5,307 shares on 09/18/2025 at $1.74, and 3,656 shares on 09/19/2025 at $1.79, totaling 11,267 shares sold and leaving Fund III with 1,859,333 shares. The filing also shows indirect holdings of 1,617,409 shares by Decheng Capital China Life Sciences USD Fund II and 891,734 shares by Decheng Capital Global Healthcare Fund (Master), LP. Footnotes explain weighted average pricing ranges and that GP entities and Dr. Xiangmin Cui may be deemed beneficial owners but disclaim direct ownership except for pecuniary interest.
Positive
- None.
Negative
- None.
Insights
TL;DR: Modest, scheduled insider sales reduced one fund's stake by 11,267 shares; holdings remain substantial across related funds.
The transactions are routine dispositions reported under Section 16, occurring over three days at weighted average prices between $1.74 and $1.83. While the sold volume (11,267 shares) appears small relative to the multi-hundred-thousand share positions held across affiliated funds, the filing clarifies indirect ownership structures and pecuniary disclaimers. For investors, these are disclosed insider sales without accompanying derivative activity or changes to control disclosures in this filing.
TL;DR: Disclosure is compliant and transparent about beneficial ownership and weighted-average sale prices; no governance red flags in this filing.
The Form 4 provides required signatures and explanatory footnotes describing the chain of beneficial ownership through GP entities and weighted average pricing ranges for multiple-lot trades. There are no indications of changes in board representation, control, or new arrangements. The reporting parties explicitly disclaim ownership beyond pecuniary interest, consistent with common private-fund reporting practices.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Ordinary Shares | 3,656 | $1.79 | $7K |
| Sale | Ordinary Shares | 5,307 | $1.74 | $9K |
| Sale | Ordinary Shares | 2,304 | $1.83 | $4K |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Footnotes (1)
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.80 to $1.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.72 to $1.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.72 to $1.85 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. These securities are held directly by Decheng Capital China Life Sciences USD Fund II, L.P. ("Fund II"). Decheng Capital Management II (Cayman), LLC ("GP II") is the general partner of Fund II. Dr. Cui is the manager of GP II. Each of Fund II, GP II and Dr. Cui may be deemed to beneficially own the securities held by Fund II. Each of GP II and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.
